Toronto Western Hospital psychedelic research trials
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Toronto Western Hospital is listed with 5 registered studies counted here, in Toronto, Canada. By compound: 2 psilocybin and 3 ketamine. By registry status: 1 recruiting, 1 enrolling by invitation, 1 active, not recruiting and 2 completed. By phase: 4 phase 2 and 1 not applicable. Reported start years run from 2022 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 5 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 2 |
| Ketamine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 20% |
| Enrolling by invitation | 1 | 20% |
| Active, not recruiting | 1 | 20% |
| Completed | 2 | 40% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 2 | 4 | 80% |
| Not applicable | 1 | 20% |
Registered studies
All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Compound |
|---|---|---|---|---|---|
| Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression | NCT07737990 | Enrolling by invitation | Not applicable | Source start: 2026-07-01 (estimated)Source date detailsStart: 2026-07-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2029-12-31 (precision: day; source type: ESTIMATED; estimated) Study completion: 2030-06-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.880Z; registry revision: 2026-07-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | NCT07569198 | Recruiting | Phase 2 | Source start: 2026-07-16 (estimated) Saved start 2026-06-01 differs from reported 2026-07-16; the saved day is not established by this observation. Source date detailsStart: 2026-07-16 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2029-01 (precision: month; source type: ESTIMATED; estimated) Study completion: 2029-08 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-07-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin | NCT06341426 | Active, not recruiting | Phase 2 | Source start: 2024-02-05 (actual)Source date detailsStart: 2024-02-05 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-07-28 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-12-28 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2026-07-09 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression | NCT05339074 | Completed | Phase 2 | Source start: 2022-08-11 (actual)Source date detailsStart: 2022-08-11 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-01-28 (precision: day; source type: ACTUAL; actual) Study completion: 2026-01-28 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.239Z; registry revision: 2026-03-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| Ketamine for Treatment-Resistant Bipolar Disorder | NCT05004896 | Completed | Phase 2 | Source start: 2022-07-04 (actual)Source date detailsStart: 2022-07-04 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-11-14 (precision: day; source type: ACTUAL; actual) Study completion: 2025-11-14 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.858Z; registry revision: 2026-03-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Country hub: Canada